Russell Investments Group’s Cellectis CLLS Stock Holding History

Russell Investments Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-98	Closed	-$193	–	3544
2023 Q2	$193	Buy	+98	New	+$188	﹤0.01%	3422

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Russell Investments Group's CLLS Position: Q3 2023 in Review

Russell Investments Group sold out of Cellectis (CLLS) in Q3 2023, closing a stake of 98 shares — an estimated $193 sold.

Russell Investments Group first reported a position in CLLS in Q2 2023 and held it in 1 quarter. The position peaked at $193 in Q2 2023. 31 funds tracked by Wall St. Rank hold CLLS as of Q3 2023.

Russell Investments Group reported no remaining Cellectis position as of Q3 2023 after selling out during the quarter.
Russell Investments Group sold 98 Cellectis shares in Q3 2023, an estimated $193.
Russell Investments Group first reported a position in Cellectis in Q2 2023 and held it in 1 quarter.
Russell Investments Group's Cellectis position peaked at $193 in Q2 2023.
31 funds tracked by Wall St. Rank held Cellectis as of Q3 2023.

Based on Russell Investments Group's 13F filing for Q3 2023, filed 13 Nov 2023.